Research programme: T3P 1017 series - T3 Pharmaceuticals
Latest Information Update: 16 Jan 2024
At a glance
- Originator T3 Pharmaceuticals
- Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies; Proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Nov 2023 Preclinical trials in Cancer in Switzerland (unspecified route), prior to November 2023 (T3 Pharmaceuticals pipeline, November 2023)